Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Parkin

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2012
Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010Neil Parkin, James Bremer, Silvia Bertagnolio
Antiviral Chemistry & Chemotherapy|December 1, 2007
A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudineKatyna Borroto-Esoda, Neil Parkin, Michael D Miller
Antimicrobial Agents and Chemotherapy|March 26, 2003
Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitorsRichard J Colonno, Alexandra Thiry, Kay Limoli, et al.
PLOS Global Public Health|October 18, 2023
Need assessment for HIV drug resistance testing and landscape of current and future technologies in low- and middle-income countriesNeil Parkin, P Richard Harrigan, Seth Inzaule, et al.
Journal of Virology|August 7, 2002
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantlyWolfgang Resch, Rainer Ziermann, Neil Parkin, et al.
Journal of Virology|July 30, 2005
Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavirWolfgang Resch, Neil Parkin, Terri Watkins, et al.
The Journal of Infectious Diseases|May 4, 2004
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimensRichard Colonno, Ronald Rose, Colin McLaren, et al.
Reviews in Medical Virology|August 5, 2025
Dried Blood Spots and Plasma Separation Cards can Broaden Access to Molecular Testing for HBV, HCV and HIVJeffrey V Lazarus, Neil Parkin, Huma Qureshi, et al.
Antiviral Research|October 3, 2022
Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravirSoo-Yon Rhee, Neil Parkin, P Richard Harrigan, et al.
Journal of Virus Eradication|September 20, 2022
A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applicationsJoseph Kin-On Lau, Nicholas Murdock, Jeffrey Murray, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2012
Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010Neil Parkin, James Bremer, Silvia Bertagnolio
Antiviral Chemistry & Chemotherapy|December 1, 2007
A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudineKatyna Borroto-Esoda, Neil Parkin, Michael D Miller
Antimicrobial Agents and Chemotherapy|March 26, 2003
Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitorsRichard J Colonno, Alexandra Thiry, Kay Limoli, et al.
PLOS Global Public Health|October 18, 2023
Need assessment for HIV drug resistance testing and landscape of current and future technologies in low- and middle-income countriesNeil Parkin, P Richard Harrigan, Seth Inzaule, et al.
Journal of Virology|August 7, 2002
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantlyWolfgang Resch, Rainer Ziermann, Neil Parkin, et al.
Journal of Virology|July 30, 2005
Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavirWolfgang Resch, Neil Parkin, Terri Watkins, et al.
The Journal of Infectious Diseases|May 4, 2004
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimensRichard Colonno, Ronald Rose, Colin McLaren, et al.
Reviews in Medical Virology|August 5, 2025
Dried Blood Spots and Plasma Separation Cards can Broaden Access to Molecular Testing for HBV, HCV and HIVJeffrey V Lazarus, Neil Parkin, Huma Qureshi, et al.
Antiviral Research|October 3, 2022
Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravirSoo-Yon Rhee, Neil Parkin, P Richard Harrigan, et al.
Journal of Virus Eradication|September 20, 2022
A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applicationsJoseph Kin-On Lau, Nicholas Murdock, Jeffrey Murray, et al.
Pageof 7